#Didyouknow
Aarti Drugs Ltd. is the largest API manufacturer of 3 molecules in the world and one of the largest manufacturer of 2 molecules
in the world? (Thread)
#aartidrugs #api
Aarti Drugs Ltd. is the largest API manufacturer of 3 molecules in the world and one of the largest manufacturer of 2 molecules
in the world? (Thread)
#aartidrugs #api
1)#Rank1 in many producing a wide variety of molecules:
2)Industry Overview:
India is the third largest active pharmaceutical ingredient (API) market in the Asia-Pacific region, which includes domestic and in-house consumption as well as exports.
The Indian API manufacturing segment can be divided into 2 sectors: branded and generic.
India is the third largest active pharmaceutical ingredient (API) market in the Asia-Pacific region, which includes domestic and in-house consumption as well as exports.
The Indian API manufacturing segment can be divided into 2 sectors: branded and generic.
3)Product Portfolio:
API- ADL manufactures API and steroids. Under API, it manufactures products like aceclofenac, ketoconazole, metformin HCl, hydroxyzine, etc. The co. manufactures steroids like hydrocortisone sodium succinate sterile, etc.
API- ADL manufactures API and steroids. Under API, it manufactures products like aceclofenac, ketoconazole, metformin HCl, hydroxyzine, etc. The co. manufactures steroids like hydrocortisone sodium succinate sterile, etc.
4)Pharma Intermediates- The co. manufactures pharma intermediates for irbesartan, Zolpidem Tartrate, Tamsulosin HCL, Leflunomide and Levocetirizine.
Speciality Chemicals- Under this, the co. manufactures products such as benzene sulphonyl chloride, benzene sulphonamide,etc.
Speciality Chemicals- Under this, the co. manufactures products such as benzene sulphonyl chloride, benzene sulphonamide,etc.
5)Revenue mix by segment (Q2FY22):
6)Benefits of the PLI Scheme:
Aarti Speciality Chemicals Limited (ASCL), a wholly-owned subsidiary of the company has received an approval under PLI
scheme.
Aarti Speciality Chemicals Limited (ASCL), a wholly-owned subsidiary of the company has received an approval under PLI
scheme.
7)Received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a
committed production capacity of 4,000 MTPA and a committed
investment outlay of ~ ₹78 crores under Target Segment III (Key
Chemical Synthesis Based KSMs/Drug Intermediates)
committed production capacity of 4,000 MTPA and a committed
investment outlay of ~ ₹78 crores under Target Segment III (Key
Chemical Synthesis Based KSMs/Drug Intermediates)
8) The co. expects ~ ₹80 crores of incentives over 6 years through this scheme which will help the company to diversify its product portfolio,increasing the top-line, and enhancing the profitability & margin profile.
Follow @FinterestC for more!
Loading suggestions...